drugset / Trial / NCT05120622
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
NaSingle-groupOpen-labelTreatment
Summary
We will conduct a Phase I trial testing whether local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab in localized bladder cancer will stimulate an effective anti-tumour immune response with minimal systemic immune response and clinical toxicity.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2022-05-01
- Completion
- 2022-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 25 mg | Other |
| Subject | Tremelimumab | Monoclonal antibody | 50 mg | Other |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | Other |